Supplementary Materials and Methods
Cell culture conditions for sorting and expression. Mammalian CHO and HEK cultures were maintained at 37°C with 8% CO 2 in humidified incubators. Suspension cultures were maintained in the same conditions, but with a shaker at 125 rpm.
Expi293F suspension HEK cells were maintained in Expi293 media (Gibco) supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, and 250 ng/mL 
with Methanosarcina mazei
PylS and 4 copies of PylT U25C . We PCR amplified PylS/PylT from our previously reported PiggyBac plasmids. 1 The four copies of PylT are arrayed in tandem, and are placed adjacent to the PylS expression cassette. Because the U6::PylT repeats are difficult to amplify by PCR, we used AccuPrime Pfx polymerase (ThermoFisher) and designed primers to be 300bp away from the start of the PylT cassette. 2 All other PCRs were done with Q5 or Fusion polymerases (NEB). pcDNA3.4, with a multiple cloning site from pcDNA3.1 inserted into the main open reading frame, was linearized by PCR.
The two PCR fragments were joined via Gibson assembly into NEB Stable cells and grown at 30°C to reduce recombination of the tRNA repeats. Heavy and light chains were cloned into their own plasmids using Gibson. Trastuzumab genes were ordered as gBlocks from IDT. UAG amber codons were introduced into Gibson homology regions for a multi-piece Gibson assembly.
A PiggyBac plasmid SE315 with 5 copies of PylT U25C , an EF1α controlled PylS, and an IRES followed by a blasticidin resistance gene was previously cloned. This plasmid was used to generate amber suppressing CHO-S lines. Trastuzumab HC::IRES::GFP (GFPspark) and LC::IRES::BFP (mTagBFP2) constructs were assembled via PCR and
Gibson into separate DNA2.0 stable CHO plasmid pD2531. The HC plasmid was cloned with both wild type and HC-118TAG variants. These plasmids were used to generate stable antibody producing lines. For all plasmids, ncAA and UGA stop codons, often in tandem, were exclusively used at the end of genes. UAG amber codons were only used at sites chosen for incorporation of CypK or BocK.
Transient expression. For transfection, Expi293F cells were grown in Expi293 media
without added antibiotics to a density of 2.5x10 6 cells/mL. HC and LC pKYM1 plasmids were mixed 1:1 and transfected using Expifectamine (Gibco) in the presence of CypK. The following day, boosters were added per the manufacturer's instructions.
Antibodies were harvested 7 days later from the supernatant.
Stable expression cell lines. Stable cell lines to produce trastuzumab with CypK were generated in two steps: insertion of the genetic code expansion machinery and integration of the heavy and light chains.
In the first step, we generated the amber suppressing lines (CHO-S HC118TAG) by using PiggyBac to insert a cassette with five copies of PylT and PylS under the U6 and EF1α promoters, respectively, into the genome ( Figure S4a ). SE315, which has 5' and 3' ITRs for integration, was co-transfected with PiggyBac transposase at a 10:1 ratio using PEI into CHO-S cells in suspension culture. A blasticidin resistance marker was included in the vector in order to select for the cells that had efficiently integrated the PylS/PylT cassette ( Figure S4b ). Two days after transfection, 10 µg/mL of blasticidin was added and the culture was maintained for 10 more days. The batch was grown without blasticidin for one week to recover. Following blasticidin selection, we sought to isolate a clonal line with high amber suppression efficiency. To this end, we transiently transfected a plasmid encoding super-folder green fluorescent protein the wild type antibody and ten from the HC118TAG antibody were scaled up and tested for expression in 2 mM CypK (synthesized as previously described). 3 The best expressing lines were pooled, and underwent another round of MSX amplification at 1 mM for two weeks in glutamine free suspension media. The batch was sorted for top 1% of double positive cells again as stated before. Ten clones from each batch were tested for expression in 2 mM CypK.
Finally, the highest expressing lines that had favorable growth properties such as growth rates and lack of clumping were tested for expression in suspension media with no glutamine, 1:100 anti-clumping agent (Gibco), and 1 mM BocK (E1610.0025, Bachem). Cultures were started at 10 6 cells/mL and run for 7 days.
Expression conditions. 100 mL of CHO-S HC118TAG suspension cell cultures was treated with 5 mM CypK (from a 100 mM CypK stock in 0.1 M NaOH), 100 units/mL penicillin, 100 ug/mL streptomycin, 250 ng/mL Amphotericin B (Antibiotic- were acquired at 280 nm. Samples below 1 mg were purified by HPLC-HIC using the conditions described in the analytical section. Elution buffer was exchanged for PBS.
The antibody was stored at 4ºC.
Quantification was carried out by western blotting in cell supernatants and by coomassie blue staining in samples purified by protein A. In both cases standards were run on the same gels and used in order to generate a calibration curve. Concentration in HIC-purified samples was quantified by UV spectrometry (Nanodrop) applying Lambert-Beer's law (ε = 225000 M -1 ·cm -1 , Mw = 148000).
vcMMAE (synthesized by ChemPartner) or tetrazineTAMRA (Jena Bioscience) (1.5 µL, 3.4 mM in DMSO) was diluted with 7.5 µL of acetonitrile and 28.5 µL of PBS.
Trastuzumab(CypK) 2 (37.5 µL, 2 mg/mL in PBS, 1 eq) was added to the solution and was allowed to react for 3 h at 25ºC. When 20 eq of tetrazine-vcMMAE were used (1.5 µL, 6.8 mM in DMSO), this compound was mixed with 15 µL of acetonitrile and 21 µL of PBS, and incubated with trastuzumab(CypK) 2 (37.5 µL, 2 mg/mL in PBS, 1 eq) for 3 h at 25ºC. Alternatively, if 2 eq of tetrazine-vcMMAE were used (1.5 µL, 1.4 mM in DMSO), they were mixed with 35 µL of PBS, and trastuzumab(CypK) 2 (37.5 µL, 2 mg/mL in PBS, 1 eq) for 20 h at 25ºC.
In the conjugation time course, samples were analyzed by HPLC-HIC at each time point without further treatment. For other analyses and applications samples were purified using size-exclusion spin columns (Zeba TM spin desalting columns, 7K MWCO, 0.5 mL).
ADCs were characterized by HPLC-HIC (Thermo Scientific TM MAbPac TM , HIC-20, 4.6
x 100 mm, 5 µm) with a flow of 1 mL/min, isocratic, with 100% A (1.5 M (NH 4 ) 2 SO 4 , 50 mM sodium phosphate pH 7.0, 5 % isopropanol) for 1 min followed by a 0-100% gradient of B (50 mM sodium phosphate pH 7.0, 20 % isopropanol) in A for 15 min. All chromatograms were acquired at 280 nm.
All antibodies were subjected to LC-MS analysis after overnight deglycosylation using . Data dependent analysis was carried out, using a resolution of 30,000 for the full MS spectrum, followed by ten MS/MS spectra. MS spectra were collected over a m/z range of 300-2000. MS/MS scans were collected using a threshold energy of 27 for higher energy collisional dissociation (HCD). LC-MS/MS data were then searched against an in-house protein database which included SwisProt (UniProt KB) using the Mascot search engine programme (Matrix Science, UK). 4 Database search parameters were set with a precursor tolerance of 10 ppm and a fragment ion mass tolerance of 0.15
Da. One missed enzyme cleavage was allowed and variable modifications for oxidized methionine, carbamidomethyl cysteine, pyroglutamic acid, phosphorylated serine, threonine and tyrosine, and cypK. MS/MS data were validated using the Scaffold programme (Proteome Software Inc., USA). 5 All data were additionally interrogated manually.
All SDS-PAGE gels were run using NuPage TM 4-12% polyacrylamide gels (BioRad) and MES buffer. were interpolated in this curve.
Fluorescence quantification was carried out by running samples diluted 1:100 with PBS on SDS-PAGE gels. Fluorescence intensity was measured by gel densitometry using Fiji.
Cytotoxicity assay. This assay was performed as previously reported. 8 Briefly, SK-BR-3 and MCF-7 cells were cultured in DMEM supplemented with 10% heat inactivated fetal bovine serum, 100 units/mL penicillin, and 100 ug/mL streptomycin. Cells were seeded in 96-well plates two days prior to treatment at 3000 cells in 100 µL/well. Two Cytotoxicity of trastuzumab-MMAE Figure S13 . The toxicity of MMAE was found to be similar in the HER2+ and HER2-cell lines tested, which shows that the increased toxicity of trastuzumab(MMAE) 2 in SK-BR-3s is not due to a different effect of the toxin on the cells. The toxicity of the MMAE peptidomimetic toxin has previously reported to be cell-independent due to its membrane permeability, underscoring the requirement of attaching it to a targeting antibody to provide selectivity. 9 Furthermore, we observed that the toxicity of MMAE was 3-4 orders of magnitude higher than the toxin with the linker (tetrazine-vcMMAE, figures 3c and 3d in the main text). The ADC was first incubated for 5 days in 90% human serum and then added to cells (+ serum dataset). Trastuzuamb(MMAE) 2 freshly diluted in PBS (-serum dataset) was added in the same experiment for comparison. As described in the experimental section for the cytotoxicity assay, these compounds were incubated 5 days with cells and viability was assessed using CellTiter Glo 2.0. Higher concentrations of the ADC could not be used in these experiments in order to maintain the normal serum levels during the treatment for the viability essay. This is why the inflection point is not observed for MCF-7 in this experiment as opposed to the plot in Figure 3d in the main text. The error bars represent the standard deviation of biological triplicates. 
